Full-Time
Staff Integrations Specialist
Posted on 9/8/2026
Twist Bioscience
1,001-5,000 employees
Produces synthetic DNA for research.
Compensation Overview
$162k - $209k/yr
South San Francisco, CA, USA
In Person
Travel to customer sites may be required.
Bachelor's
 Solution Engineering (1) |
|---|
Get referred to Twist Bioscience
See people who can refer or advise you
- Bachelor’s degree in Computer Science, Engineering, Information Systems, or a related scientific/technical field.
- 10+ years of hands-on experience as a business systems analyst, technical integrations specialist, solution architect, or technical delivery professional within life sciences, technology, or related fields.
- A proven track record of operating as a lead technical authority or staff-level individual contributor influencing cross-functional teams.
- A proven track record as a senior- or lead-level technical contributor in customer-facing integration, technical product management, or systems engineering roles.
- Experience with application programming interfaces, web services, and authentication methods.
- Experience with B2B eProcurement platforms including Coupa, Jaggaer, SAP Ariba, and Oracle/PeopleSoft, and integration formats including cXML, OCI, EDI, JSON, and XML.
- Proven ability to work with customers and map customer-specific needs.
- Demonstrated ability to manage multiple complex, parallel technical implementations in a fast-paced, agile environment without direct management oversight.
- Ability to articulate complex technical concepts to both executives and software engineers.
- High ownership and comfort operating across organizational boundaries.
- Customer empathy and a proactive, problem-solving mindset.
- Serve as the subject matter expert for customer-facing integrations by establishing standard operating procedures, design patterns, and scalability blueprints for APIs and B2B eProcurement technologies.
- Lead end-to-end delivery of high-value, highly complex API-based integrations and B2B punchout solutions, including authentication, custom data mapping, error handling, and real-time monitoring.
- Partner with Product and Information and Business Technology leadership to shape the API and Punchout product roadmap, prioritizing feature requests, system enhancements, and architectural refactoring.
- Work directly with enterprise customers’ IT, procurement, and scientific teams to translate scientific requirements into API intake and data-mapping specifications.
- Direct and optimize B2B eProcurement punchout integrations across Coupa, Jaggaer, SAP Ariba, Oracle/PeopleSoft, and protocols including cXML, OCI, and EDI.
- Act as the primary liaison between customer procurement teams, third-party middleware providers, and internal product and business stakeholders to align on integration standards and mitigate go-live risks.
- Establish and maintain technical documentation, integration playbooks, API specifications, and troubleshooting frameworks.
- Travel to customer sites as needed to assist with complex onboarding or resolve mission-critical integration bottlenecks.
- Prior experience as a Technical Product Manager, Solution Architect, or Sales Engineer/Solutions Architect.
- Direct experience working alongside enterprise Sales or Customer Success teams.
- Hands-on experience with enterprise eCommerce platforms and core business applications such as Salesforce.com and SAP ERP/CRM.
Twist Bioscience designs and manufactures synthetic DNA for biotech, pharmaceutical, and research use. It uses a proprietary platform that rapidly produces custom DNA sequences and a smart algorithm to verify synthesis feasibility before production, with customers submitting requests and receiving DNA, DNA data storage, or NGS services. It differentiates itself by offering high-quality DNA at competitive prices, the ability to handle complex sequences, and an integrated platform with a broad product range for fast delivery. Its goal is to be a reliable, leading supplier of synthetic DNA and genomics tools that accelerates biotech and drug development for a wide range of clients.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
South San Francisco, California
Founded
2013
Get referred to Twist Bioscience
See people who can refer or advise you
Simplify's Take
What believers are saying
- Twist raised FY2026 revenue guidance to $456–457 million after Q3 revenue hit $118.4 million.
- AI drug discovery and genomic database demand drove 39% growth in DNA Synthesis and Protein Solutions.
- Management expects adjusted EBITDA breakeven in Q4 FY2026, improving credibility with investors and recruits.
What critics are saying
- August 2026’s $250 million offering and prior dilution pressure per-share returns.
- The $17.05 million securities settlement finalizes November 18, 2026, prolonging governance overhang.
- Illumina, Thermo Fisher, and synthetic biology peers can compress pricing; manufacturing setbacks threaten relevance.
What makes Twist Bioscience unique
- Twist’s silicon-based synthesis platform still delivers high-throughput, complex DNA at scale.
- August 2026 Complex Genes expands into high-GC, repetitive constructs competitors struggle to make.
- Automated NGS workflows with Volta Labs embed Twist deeper into lab operations.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Life Insurance
401(k) Retirement Plan
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 0%2 year growth
↑ 0%Twist Bioscience raised $300 million through a follow-on stock offering at $96 per share in early August 2026. The synthetic biology company simultaneously increased its fiscal 2026 revenue guidance to $456–457 million and reported third-quarter sales of $118.38 million, though it posted a net loss of $35.05 million. The firm is also working to resolve legacy securities litigation through a proposed $17.05 million class-action settlement. Fourth-quarter revenue guidance stands at $123–124 million. Despite the upgraded outlook, analysts remain cautious about Twist's path to profitability. Some project continued losses alongside approximately 15% annual revenue growth. The company's share price rose 26.3% following the announcements, though concerns about ongoing dilution and losses persist.
Twist Bioscience has launched an underwritten public offering of $250 million of common stock. The synthetic biology company has also granted underwriters a 30-day option to purchase up to an additional $37.5 million of shares. All shares in the offering are being sold by Twist Bioscience. The company plans to use the proceeds to fund research and development investments, expand manufacturing capacity, develop product offerings, and support general corporate purposes.
Twist Bioscience reported fiscal Q3 revenue of $118.4 million, up 23% year over year, marking its 14th consecutive quarter of growth. DNA Synthesis and Protein Solutions revenue rose 39% to $56.6 million, whilst NGS Applications revenue increased 12% to approximately $61.8 million. The company raised its fiscal 2026 revenue guidance to $456 million–$457 million, representing approximately 21% year-over-year growth at the midpoint. Gross margin improved to 52.8%, up 120 basis points sequentially. AI-enabled drug discovery emerged as a significant growth driver. Management expressed confidence in achieving triple-digit order growth in both fiscal 2026 and fiscal 2027. Twist reiterated its expectation to reach adjusted EBITDA breakeven in the fiscal fourth quarter. The company formally launched its Complex Genes offering after early-access customers ordered more than 1,800 constructs.
Twist Bioscience Corporation has been highlighted as a top contributor by Osterweis Capital Management in its Q1 2026 investor letter. The synthetic DNA manufacturer closed at $87.56 per share on 18 June 2026, with a market capitalisation of $5.45 billion. The company, which produces synthetic genomic material for drug discovery and genomic testing, is positioned in the expanding liquid biopsy field. Notably, Twist is being used by technology companies as an outsourced laboratory for building genomic databases for AI large language models, a new growth area that contributed to strong Q1 performance. Twist's Q2 fiscal 2026 revenue reached $110.7 million, up over 19% year-on-year. Hedge fund holdings increased to 30 portfolios by end of Q1 2026, up from 24 the previous quarter.
Eli Lilly and Twist Bioscience are leveraging AI to accelerate drug development, representing different opportunities in healthcare's AI evolution. Lilly, a pharmaceutical giant dating to the 1870s, is partnering with OpenAI and Nvidia on drug discovery and AI co-innovation labs. Trading near $1,120, Lilly shares have gained 36% over the past year and over 400% in five years. First-quarter 2026 revenue jumped 56% to $19.8 billion, whilst net income climbed 168% to $7.4 billion. The company's newly approved weight-loss pill, Foundayo, could significantly expand its patient base. Twist Bioscience, founded in 2013, produces synthetic DNA for pharmaceutical testing. Its shares trade around $83, up 136% over the past year, though down 26% over five years, presenting a higher-risk growth opportunity.